Silencing of the long non‑coding RNA GHET1 inhibits cell proliferation and migration of renal cell carcinoma through epithelial‑mesenchymal transition

Xie,Wenjie; Liu,Xin; Chen,Qiang; Ma,Ming; Yang,Xiaorong; Gong,Binbin; Sun,Ting; Chen,Jie

doi:10.3892/ol.2019.9967

Silencing of the long non‑coding RNA GHET1 inhibits cell proliferation and migration of renal cell carcinoma through epithelial‑mesenchymal transition

Authors:
- Wenjie Xie
- Xin Liu
- Qiang Chen
- Ming Ma
- Xiaorong Yang
- Binbin Gong
- Ting Sun
- Jie Chen
View Affiliations

Affiliations: Department of Urology, The First Affiliated Hospital of Nanchang University, Nanchang, Jiangxi 330000, P.R. China, Department of Blood Transfusion, Jiangxi Provincial Children's Hospital, Nanchang, Jiangxi 330000, P.R. China
Published online on: January 25, 2019 https://doi.org/10.3892/ol.2019.9967
Pages: 3173-3180
Copyright: © Xie et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Long non‑coding RNAs (lncRNAs) have been demonstrated to serve vital roles in renal cell carcinoma (RCC) development. Gastric carcinoma high expressed transcript 1 (GHET1) regulates numerous biological processes in cancer cells. However, the biological role of GHET1 in RCC has not yet been identified. This study aimed to investigate the role of GHET1 in RCC. In the present study, the expression of GHET1 in RCC tissues and the 786‑O, A498 and 293 cell lines was assessed by reverse transcription‑quantitative polymerase chain reaction. Cell Counting Kit‑8, colony formation and cell scratch assays were used to determine the effects of GHET1 on tumorigenesis. Western blotting was performed to examine the effect of GHET1 on epithelial‑mesenchymal transition (EMT) in RCC cells. GHET1 expression was significantly increased in the RCC samples in comparison with adjacent tissues. High expression levels of GHET1 were associated with distant metastasis and clinical stage severity, thus, high GHET1 expression may serve as a predictor for a poor prognosis. In addition, RCC cells presented higher GHET1 mRNA and protein expression levels compared with in 293 cells. Furthermore, silencing GHET1 suppressed cell growth, weakened cell migration and inhibited EMT of RCC cells in vitro. In conclusion, the present study suggested that GHET1 may be considered a therapeutic target for the treatment or prevention of RCC.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2018. CA Cancer J Clin. 68:7–30. 2018. View Article : Google Scholar : PubMed/NCBI
2	Lam JS, Leppert JT, Belldegrun AS and Figlin RA: Novel approaches in the therapy of metastatic renal cell carcinoma. World J Urol. 23:202–212. 2005. View Article : Google Scholar : PubMed/NCBI
3	Janzen NK, Kim HL, Figlin RA and Belldegrun AS: Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am. 30:843–852. 2003. View Article : Google Scholar : PubMed/NCBI
4	Kugel JF and Goodrich JA: Non-coding RNAs: Key regulators of mammalian transcription. Trends Biochem Sci. 37:144–151. 2012. View Article : Google Scholar : PubMed/NCBI
5	Fachel AA, Tahira AC, Vilella-Arias SA, Maracaja-Coutinho V, Gimba ER, Vignal GM, Campos FS, Reis EM and Verjovski-Almeida S: Expression analysis and in silico characterization of intronic long noncoding RNAs in renal cell carcinoma: Emerging functional associations. Mol Cancer. 12:1402013. View Article : Google Scholar : PubMed/NCBI
6	Bhan A and Mandal SS: LncRNA HOTAIR: A master regulator of chromatin dynamics and cancer. Biochim Biophys Acta 1856. 151–164. 2015.
7	Cui Y, Zhang F, Zhu C, Geng L, Tian T and Liu H: Upregulated lncRNA SNHG1 contributes to progression of non-small cell lung cancer through inhibition of miR-101-3p and activation of Wnt/β-catenin signaling pathway. Oncotarget. 8:17785–17794. 2017.PubMed/NCBI
8	She K, Yan H, Huang J, Zhou H and He J: miR-193b availability is antagonized by LncRNA-SNHG7 for FAIM2-induced tumour progression in non-small cell lung cancer. Cell Prolif. 51:2018. View Article : Google Scholar : PubMed/NCBI
9	Yang F, Xue X, Zheng L, Bi J, Zhou Y, Zhi K, Gu Y and Fang G: Long non-coding RNA GHET1 promotes gastric carcinoma cell proliferation by increasing c-Myc mRNA stability. FEBS J. 281:802–813. 2014. View Article : Google Scholar : PubMed/NCBI
10	Zhou J, Li X, Wu M, Lin C, Guo Y and Tian B: Knockdown of long noncoding RNA GHET1 inhibits cell proliferation and invasion of colorectal cancer. Oncol Res. 23:303–309. 2016. View Article : Google Scholar
11	Hugo H, Ackland ML, Blick T, Lawrence MG, Clements JA, Williams ED and Thompson EW: Epithelial-mesenchymal and mesenchymal-epithelial transitions in carcinoma progression. J Cell Physiol. 213:374–383. 2007. View Article : Google Scholar : PubMed/NCBI
12	Weischenfeldt J, Simon R, Feuerbach L, Schlangen K, Weichenhan D, Minner S, Wuttig D, Warnatz HJ, Stehr H, Rausch T, et al: Integrative genomic analyses reveal an androgen-driven somatic alteration landscape in early-onset prostate cancer. Cancer Cell. 23:159–170. 2013. View Article : Google Scholar : PubMed/NCBI
13	Thiery JP, Acloque H, Huang RY and Nieto MA: Epithelial-mesenchymal transitions in development and disease. Cell. 139:871–890. 2009. View Article : Google Scholar : PubMed/NCBI
14	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
15	Abell AN and Johnson GL: Implications of mesenchymal cells in cancer stem cell populations: Relevance to EMT. Curr Pathobiol Rep. 2:21–26. 2014. View Article : Google Scholar : PubMed/NCBI
16	Thiounn N, Mathiot C, Dorval T, Flam TA, Tartour E, Mosseri V, Zerbib M, Fridman WH and Debre B: Lack of efficacy of low-dose subcutaneous recombinant interleukin-2 and interferon-alpha in the treatment of metastatic renal cell carcinoma. Br J Urol. 75:586–589. 1995. View Article : Google Scholar : PubMed/NCBI
17	Abel EJ and Wood CG: Cytoreductive nephrectomy for metastatic RCC in the era of targeted therapy. Nat Rev Urol. 6:375–383. 2009. View Article : Google Scholar : PubMed/NCBI
18	Faris JE and Michaelson MD: Targeted therapies: Sunitinib versus interferon-alpha in metastatic RCC. Nat Rev Clin Oncol. 7:7–8. 2010. View Article : Google Scholar : PubMed/NCBI
19	Grünwald V, Weikert S, Seidel C, Busch J, Johannsen A, Fenner M, Reuter C, Ganser A and Johannsen M: Efficacy of sunitinib re-exposure after failure of an mTOR inhibitor in patients with metastatic RCC. Onkologie. 34:310–314. 2011. View Article : Google Scholar : PubMed/NCBI
20	Cao Y, Xu R, Xu X, Zhou Y, Cui L and He X: Downregulation of lncRNA CASC2 by microRNA-21 increases the proliferation and migration of renal cell carcinoma cells. Mol Med Rep. 14:1019–1025. 2016. View Article : Google Scholar : PubMed/NCBI
21	Zhai W, Sun Y, Guo C, Hu G, Wang M, Zheng J, Lin W, Huang Q, Li G, Zheng J and Chang C: LncRNA-SARCC suppresses renal cell carcinoma (RCC) progression via altering the androgen receptor(AR)/miRNA-143-3p signals. Cell Death Differ. 24:1502–1517. 2017. View Article : Google Scholar : PubMed/NCBI
22	Hong Q, Li O, Zheng W, Xiao WZ, Zhang L, Wu D, Cai GY, He JC and Chen XM: LncRNA HOTAIR regulates HIF-1α/AXL signaling through inhibition of miR-217 in renal cell carcinoma. Cell Death Dis. 8:e27722017. View Article : Google Scholar : PubMed/NCBI
23	Jin L, He Y, Tang S and Huang S: LncRNA GHET1 predicts poor prognosis in hepatocellular carcinoma and promotes cell proliferation by silencing KLF2. J Cell Physiol. 233:4726–4734. 2018. View Article : Google Scholar : PubMed/NCBI
24	Zhou HY, Zhu H, Wu XY, Chen XD, Qiao ZG, Ling X, Yao XM and Tang JH: Expression and clinical significance of long-non-coding RNA GHET1 in pancreatic cancer. Eur Rev Med Pharmacol Sci. 21:5081–5088. 2017.PubMed/NCBI
25	Guan ZB, Cao YS, Li Y, Tong WN and Zhuo AS: Knockdown of lncRNA GHET1 suppresses cell proliferation, invasion and LATS1/YAP pathway in non small cell lung cancer. Cancer Biomark. 21:557–563. 2018. View Article : Google Scholar : PubMed/NCBI
26	Song R, Zhang J, Huang J and Hai T: Long non-coding RNA GHET1 promotes human breast cancer cell proliferation, invasion and migration via affecting epithelial mesenchymal transition. Cancer Biomark. 22:565–573. 2018. View Article : Google Scholar : PubMed/NCBI
27	Savagner P: The epithelial-mesenchymal transition (EMT) phenomenon. Ann Oncol. 21 Suppl 7:vii89–vii92. 2010. View Article : Google Scholar : PubMed/NCBI
28	Tam WL and Weinberg RA: The epigenetics of epithelial-mesenchymal plasticity in cancer. Nat Med. 19:1438–1449. 2013. View Article : Google Scholar : PubMed/NCBI
29	Djebali S, Davis CA, Merkel A, Dobin A, Lassmann T, Mortazavi A, Tanzer A, Lagarde J, Lin W, Schlesinger F, et al: Landscape of transcription in human cells. Nature. 489:101–108. 2012. View Article : Google Scholar : PubMed/NCBI
30	Xu ZY, Yu QM, Du YA, Yang LT, Dong RZ, Huang L, Yu PF and Cheng XD: Knockdown of long Non-coding RNA HOTAIR suppresses tumor invasion and reverses Epithelial-mesenchymal transition in gastric cancer. Int J Biol Sci. 9:587–597. 2013. View Article : Google Scholar : PubMed/NCBI